-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$6.00631.71% Upside
Vor Biopharma Inc. Frequently Asked Questions
-
What analysts cover Vor Biopharma Inc.?
Vor Biopharma Inc. has been rated by research analysts at Goldman Sachs in the past 90 days.